company background image
VG20 logo

Avinger DB:VG20 Stock Report

Last Price

€5.43

Market Cap

€4.0m

7D

0%

1Y

-68.5%

Updated

10 Dec, 2023

Data

Company Financials +

VG20 Stock Overview

A commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. More details

VG20 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Avinger, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Avinger
Historical stock prices
Current Share PriceUS$5.43
52 Week HighUS$21.15
52 Week LowUS$5.40
Beta1.29
1 Month Change0%
3 Month Change0.56%
1 Year Change-68.52%
3 Year Change-91.04%
5 Year Change-99.26%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

VG20DE Medical EquipmentDE Market
7D0%-3.3%-2.0%
1Y-68.5%-8.5%6.9%

Return vs Industry: VG20 underperformed the German Medical Equipment industry which returned -2.5% over the past year.

Return vs Market: VG20 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is VG20's price volatile compared to industry and market?
VG20 volatility
VG20 Average Weekly Movementn/a
Medical Equipment Industry Average Movement6.7%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: VG20 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine VG20's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200773Jeff Soinskiavinger.com

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.

Avinger, Inc. Fundamentals Summary

How do Avinger's earnings and revenue compare to its market cap?
VG20 fundamental statistics
Market cap€4.02m
Earnings (TTM)-€17.29m
Revenue (TTM)€7.20m

0.6x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VG20 income statement (TTM)
RevenueUS$7.75m
Cost of RevenueUS$5.44m
Gross ProfitUS$2.31m
Other ExpensesUS$20.92m
Earnings-US$18.61m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-13.58
Gross Margin29.84%
Net Profit Margin-240.18%
Debt/Equity Ratio-1,018.8%

How did VG20 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/10 06:24
End of Day Share Price 2023/09/12 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avinger, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marc WiesenbergerB. Riley Securities, Inc.
Sean LavinBTIG
Jason MillsCanaccord Genuity